Skip to content

Attributes and Skills Provided to the Board:

Expertise Provided to the Board:

Dipal Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors, where he previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. Earlier in his career, he has held senior-level positions at a healthcare private equity fund and Catalent, Merrill Lynch’s Investment Banking Group, as well as several roles at Eli Lilly and Company. Mr. Doshi brings significant experience in the biotechnology and pharmaceutical industries. His experience in strategy, operational and commercial growth, and perspective as a current public company CEO will be additive to the Board.